International Stem Cell(ISCO)
SAN DIEGO, CABiotechnology
Focus: International Stem Cell is a publicly traded San Diego-based biotech focused on proprietary stem cell induction technology for cell therapy applications. The company operates at modest scale with $9M in FY 2025 revenue and a highly constrained pipeline across multiple therapeutic indications.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
1
Should You Work at International Stem Cell?
AI assessmentInternational Stem Cell presents high execution and survival risk; only consider if you have equity upside conviction and tolerance for pre-revenue biotech volatility despite public status.
Why Work Here
- Publicly traded company (ticker: ISCO) offers liquidity and transparency vs. early-stage private biotech
- Focused specialty in stem cell induction and cell therapy represents a differentiated scientific platform
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$9M
Pipeline & Clinical Trials
High frequency pure tone audiometry
Hearing Loss, SensorineuralClinical Trials (1)
NCT04270916Prevalence and Impact on QoL From Ototoxicity in Cancer Survivors
N/AHelp build intelligence for International Stem Cell
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.